Search your stocks

Share

Profile

PPLPHARMAPiramal Pharma Ltd.

208.07(+2.33%)

1W: +2.60%

1M: +5.06%

1Y: +56.53%

Financials

Charts

YoY Net Sales

Operating Margin

EPS Growth

Pros & Cons

POSITIVES

Revenue growth in the latest quarter shows a strong upward trend, reflecting robust demand for pharmaceuticals.
Operating margin improvement indicates better cost management and operational efficiency compared to previous quarters.
Strategic investments in R&D are beginning to yield results, fostering innovation and potential new product launches.

NEGATIVES

Declining net profit margin raises concerns about profitability and cost pressures affecting the bottom line.
Increased debt levels pose risks related to financial stability and could impact future growth opportunities.
Sales growth has slowed compared to prior quarters, indicating potential market saturation or increased competition.

Quarterly Results Data

Field	Trend	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue		1,911.38	1,958.57	2,552.36	1,951.14	2,241.75	2,204.22	2,754.07	1,933.71
Expenses		1,940.12	1,982.40	2,332.78	2,038.16	2,200	2,166.60	2,539.52	2,110.44
Operating Profit		-28.74	-23.83	219.58	-87.02	41.75	37.62	214.55	-176.73
Other Income		49.19	61.51	26.38	19.54	61.11	12.13	42.03	58.40
Interest		109.87	105.88	114.22	106.96	107.64	103.31	103.68	86.15
Depreciation		184.51	186.32	196.13	184.55	192.22	196.81	242.76	197.28
Profit Before Tax		39.56	19.36	227.48	-45.08	120.12	66.80	272.80	-79.02
Tax		34.54	9.25	126.21	43.56	97.53	63.12	119.30	2.68
Net Profit		5.02	10.11	101.27	-88.64	22.59	3.68	153.50	-81.70
Eps in Rs		0.04	0.08	0.77	-0.67	0.17	0.03	1.16	-0.62